Details of Disease

General Information of Disease (ID: DISTJXPA)

• Disease Name: Bone metastases
• Disease Class: 2D50-2E2Z: Metastatic tumour
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISTJXPA: Bone metastases
• ICD Code:
  ICD-11: ICD-11: 2D50
  ICD-10: ICD-10: C79.5
  ICD-9: ICD-9: 198.5
  Expand ICD-11: '2E03
  Expand ICD-10: 'C79.5
  Expand ICD-9: 198.5

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 6 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
153Sm-EDTMP	DM7DWMI	Approved	Small molecular drug	[1]
99mTc-besilesomab	DMJTA2P	Approved	Monoclonal antibody	[1]
Mebiphon	DMQCYZA	Approved	NA	[1]
Rhenium-186 etidronate	DMRM4E9	Approved	NA	[1]
Sodium phosphate P 32	DMW5J1L	Approved	Small molecular drug	[1]
Temoporfin	DMTNM5C	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MCS-110	DM0CL4I	Phase 2	NA	[2]
MER-101	DMUTCDY	Phase 2	Small molecular drug	[3]
CEP-37251	DMYXQBF	Phase 1	NA	[4]
GLPG-0187	DMWIHR6	Phase 1	NA	[5]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Relacatib	DMLJEFH	Discontinued in Phase 2	Small molecular drug	[6]
Sn-117m-DTPA	DMB8E1J	Discontinued in Phase 2	NA	[7]
AUX-202	DMFOQLM	Terminated	NA	[8]

This Disease is Treated as An Indication in 6 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AM-3701	DMZVLJH	Investigative	NA	[9]
APX-007	DMXAO0D	Investigative	NA	[10]
APX-008	DM1OPIZ	Investigative	NA	[10]
CT-400P	DM161LE	Investigative	NA	[10]
MIV-710	DM13TUY	Investigative	NA	[9]
P-17	DMAKZ2H	Investigative	NA	[10]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] ClinicalTrials.gov (NCT01643850) MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS). U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT00636740) Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT01159873) Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women. U.S. National Institutes of Health.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026321)
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7862).
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005379)
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019517)
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2350).
• [10] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.